Figure 2.

Association between baseline lipoprotein(a) level and atherosclerotic cardiovascular disease risk in placebo and statin treatment arms. Atherosclerotic cardiovascular disease risk increases log-linearly with increasing lipoprotein(a) (Lp[a]) levels in both the placebo and statin treatment arms. Hazard ratios were calculated using a reference Lp(a) level of 5 mg/dL. Adjusted for age, sex, history of vascular disease, diabetes, smoking, systolic blood pressure, baseline low-density lipoprotein cholesterol level, and high-density lipoprotein cholesterol level, and stratified by trial and treatment assignment.